[1] DARRYLE D. SCHOEPP James A M David E Jane. Pharmacological agents acting at subtypes of metabotropic glutamate receptors[J]. Neuropharmacology, 1999, 38 10: Pages 1431-1476. DOI:
10.1016/s0028-3908(99)00092-1[2] JON E. HAWKINSON Paul L W Manuel Acosta Burruel. The metabotropic glutamate receptor antagonist l-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase[J]. European journal of pharmacology, 1996, 307 2: Pages 219-225. DOI:
10.1016/0014-2999(96)00253-1[3] S OTANI W B L J A Connor. Long-term potentiation and evidence for novel synaptic association in CA1 stratum oriens of rat hippocampus.[J]. Learning & memory, 1995, 2 2: 101-106. DOI:
10.1101/lm.2.2.101[4] HAO LI Gang H Jian Hua Ding. Group I mGluR ligands fail to affect 6-hydroxydopamine- induced death and glutamate release of PC12 cells.[J]. Acta Pharmacologica Sinica, 2003, 24 7: 641-645.
[5] ZHAO-HUI XU. Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome.[J]. Molecular Neurodegeneration, 2012, 7: 24. DOI:
10.1186/1750-1326-7-24